AEON Biopharma (AEON) Financials

AEON Biopharma remains a pre-revenue company with continuing operating losses. Revenue, cost of revenue and gross profit were reported at zero in every income statement provided from the second quarter of 2024 through the second quarter of 2026. This indicates that the company has not yet generated commercial sales from its development programs during the period analyzed.

Quarterly losses have generally improved from the unusually large losses recorded in early 2024 and late 2025. Net loss attributable to common shareholders was $2.9 million in Q2 2026, compared with $11.8 million in Q1 2026 and $37.1 million in Q4 2025. However, the improvement was driven partly by a $3.1 million gain in other income, while operating expenses remained high at $5.9 million. AEON still has no operating revenue to support these costs.

Cash flow remains a significant concern. AEON used $3.7 million in operating cash during Q2 2026, following operating cash outflows of $2.6 million in Q1 2026, $4.7 million in Q4 2025 and $2.1 million in Q2 2025. The company has repeatedly relied on equity or debt financing to fund its operations. Cash and equivalents declined from $10.4 million at the end of Q1 2024 to $3.4 million at June 30, 2026, despite multiple financing transactions.

The balance sheet shows limited liquidity and substantial accumulated deficits. At June 30, 2026, current assets totaled $4.0 million versus current liabilities of $7.3 million, implying a current ratio of approximately 0.54. Total liabilities of $21.3 million exceeded total assets of $5.9 million, resulting in negative shareholders’ equity of $15.4 million. Other noncurrent operating liabilities totaled $12.2 million, while long-term debt was $1.8 million.

• Quarterly losses narrowed materially: Q2 2026’s $2.9 million loss attributable to common shareholders was substantially below the $11.8 million Q1 loss and $37.1 million Q4 2025 loss.
• SG&A spending declined: Selling, general and administrative expense fell to $3.0 million in Q2 2026 from $3.9 million in both Q1 2026 and Q4 2025.
• Debt levels have improved from early 2024: Long-term debt declined to $1.8 million at June 30, 2026 from $13.3 million at March 31, 2024, although other liabilities remain significant.
• Research spending increased: R&D expense rose to $2.9 million in Q2 2026 from $2.0 million in Q1 2026. This may support development efforts, but it also increases cash consumption until a product reaches the market.
• Reported earnings data contain inconsistencies: Q2 2026 continuing-operations loss attributable to common shareholders was listed as $2.9 million, while consolidated net loss and cash-flow net income were listed as $1.2 million. Investors should review the company’s filing for the detailed reconciliation.
• AEON remains pre-revenue: Revenue has been reported at zero across all supplied quarterly income statements, leaving the company dependent on external capital.
• Operating cash burn persists: The company generated no operating cash in the periods provided and used $3.7 million in Q2 2026 alone.
• Cash reserves are shrinking: Cash fell from $16.2 million at September 30, 2023 and $10.4 million at March 31, 2024 to just $3.4 million at June 30, 2026.
• Liquidity is weak: June 2026 current liabilities were roughly 1.8 times current assets, leaving insufficient current assets to cover near-term obligations.
• Negative equity and financing dependence increase risk: Total equity was negative $15.4 million at June 30, 2026, while recent cash inflows included $5.9 million of financing in Q1 2026 and $886,000 of common-equity issuance in Q2. Additional fundraising could dilute existing shareholders.